AbbVie has successfully tested a new drug for the treatment of rheumatoid arthritis

News Project Concord
by

In the phase IIA study was developed by company AbbVie ABBV drug-3373 demonstrated a positive effect on disease activity in patients with rheumatoid arthritis. A new drug is a conjugated monoclonal antibody with the drug (ADC) consisting of an inhibitor of tumor necrosis factor (TNF) and patented modulator of glucocorticoid receptor (GRM).

The primary endpoint of the study was change in disease activity index in 28 joints with determination of C-reactive protein (DAS28-CRP) from baseline to 12 weeks. To assess the effectiveness of the new tool were compared the data obtained in the study of drug ABBV-3373, and the results, sobrando in previous studies adalimumab. It was also compared data obtained in the study of drug ABBV-3373, and the results of current and previous studies adalimumab.

The results of both comparisons showed statistically significant superiority of the new therapy over adalimumab. In addition, measuring the level of cortisol in blood serum during 12 weeks show that the ABBV drug-3373 did not exert systemic effects associated with the glucocorticoids.

Developed by the drug company AbbVie ABBV-3373 is an experimental ADC consisting of the latest modulator of glucocorticoid receptor (GRM) associated with adalimumab influencing TNF mediated signaling pathways involved in the development of inflammation through delivery of corticosteroids directly to the activated immune cell expressing associated with membrane TNF. This ADC was designed for targeted effects on activated immune cells, causing a significant decrease in inflammation and minimizing systemic side effects associated with the glucocorticoids.

Leave a Reply

Your email address will not be published. Required fields are marked *

Releated

For the six months Kurgan “Synthesis” increased revenue by 42%

Revenue of JSC “Sintez” (part of the Allium Group) for 6 months of 2020 has increased by 42% year-on-year to 6,767 billion. Net profit reached 752.9 million roubles that on 23% more than in the same period last year. Export sales grew by 36% year-on-year, exceeding 1 billion rubles, told in the company. Secondary sales […]

by

Russia confirmed on 5 065 new cases COVID-19

In recent days in Russia identified 5 065 new cases of coronavirus in 83 regions. Died 114 people, fully recovered 6 568 patients. In Moscow confirmed 688 new cases of coronavirus. The average rate of increase of new cases for the first two weeks of August is 0.28%. This figure compares with the first two […]

by